Unknown

Dataset Information

0

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.


ABSTRACT: The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants with a first-year RSV hospitalisation risk of >?10% resulted in a QALY gain of 0.02 (0.931 vs. 0.929) per patient against additional cost of €472 compared to no prophylaxis (ICER €214,748/QALY). The ICER falls below a threshold of €80,000 per QALY when RSV prophylaxis cost would be lowered from €928 (baseline) to €406 per unit. At a unit cost of €97, RSV prophylaxis would be cost saving. CONCLUSIONS:Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.

SUBMITTER: Blanken MO 

PROVIDER: S-EPMC5748402 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.

Blanken Maarten O MO   Frederix Geert W GW   Nibbelke Elisabeth E EE   Koffijberg Hendrik H   Sanders Elisabeth A M EAM   Rovers Maroeska M MM   Bont Louis L  

European journal of pediatrics 20171122 1


The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER)  ...[more]

Similar Datasets

| S-EPMC10853977 | biostudies-literature
| S-EPMC6030843 | biostudies-literature
| S-EPMC4025592 | biostudies-literature
| S-EPMC6260117 | biostudies-other
| S-EPMC5074917 | biostudies-literature
| S-EPMC5820240 | biostudies-literature
| S-EPMC9377037 | biostudies-literature
| S-EPMC8038138 | biostudies-literature
| S-EPMC5944988 | biostudies-literature
| S-EPMC10314303 | biostudies-literature